Older, younger patients with metastatic pancreatic cancer have similar survival
the ONA take:
Older patients metastatic pancreatic cancer are less likely to receive chemotherapy and receive fewer agents yet have similar overall survival compared with younger patients with metastatic disease, according to a recent study published online ahead of print in the Journal of Geriatric Oncology.
For the study, researchers at Fox Chase Cancer Center in Philadelphia, PA, sought to compare patterns of care and outcomes of patients with metastatic pancreatic cancer who are less than 65 years of age with those older than 65 years of age treated at their institution.
The researchers analyzed the medical records of 579 patients who were treated between 2000 and 2010. Results showed that patients older than 65 years were less likely to receive any chemotherapy for their cancer. In addition, those over 65 who were treated were less likely to receive more than 1 agent.
Researchers found that survival was comparable between the two cohorts. In both groups, a higher number of treatment agents and lung metastatases was associated with longer overall survival, while liver metastates were associated with worse survival.
The findings suggest that older patients with metastatic pancreatic cancer with good performance status should be encouraged to enroll onto clinical trials.
Older patients metastatic pancreatic cancer are less likely to receive chemotherapy compared with younger patients with metastatic disease.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|